[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Aarhus\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":698},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,151,0,25,[9,41,74,104,133,163,192,227,253,277,297,327,355,385,407,431,459,486,515,535,557,582,621,647,674],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100520642","phase-4-the-optimised-use-of-romozosumab-study-100520642",false,"NCT06059222","The Optimised Use of Romozosumab Study","OPTIMIST","Inclusion Criteria:\n\n* Postmenopausal women (postmenopausal for at least two years)\n* BMD T-score \\\u003C -2.5 at lumbar spine, total hip, or femoral neck\n* Osteoporotic fracture within the last 3 years at the spine, hip, pelvis, humerus or forearm after the age of 50 years.\n\nExclusion Criteria:\n\n* Osteoporosis treatment including hormone replacement therapy within the last 5 years\n* Metabolic bone disease\n* Known disorders affecting bone metabolism, e.g., uncontrolled thyrotoxicosis, liver dysfunction (baseline phosphatase higher than twice upper limit), rheumatism, severe COPD (chronic obstructive pulmonary disease), hypopituitarism, Cushing's disease\n* Ongoing treatment with glucocorticoids (systemic)\n* Estimated glomerular filtration rate (eGFR) \\\u003C 35 mL\u002Fmin\n* Contraindications for zoledronate according to the Supplementary protection certificates (SPC)\n* Contraindications for romosozumab according to the SPC\n* For the subgroup with Jamshidi biopsies contraindications for local anaesthetics according to the SPC\n* For the subgroup with Jamshidi biopsies contraindications for tetracycline or doxycykline according to the SPC","FEMALE","50 Years",{"count":20,"type":21},270,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","OPTIMIST is a two-year, randomised, active controlled, open-label, multicentre intervention trial. OPTIMIST includes 3 treatment groups each comprising combinations of romosozumab (ROMO) and zoledronate (ZOL) treatment used in standard doses (210 mg monthly (sc) and 5 mg yearly (iv), respectively).\n\nThe study will investigate if it is possible to maximize the effect of romosozumab by giving it in 2 periods of 6 months interrupted by zoledronate for 12 months compared to romosozumab for 12 months uninterrupted followed by zoledronate for 12 months. The investigators will also evaluate if 6 months of romosozumab followed by 18 months of zoledronate is non-inferior to the standard regimen of romosozumab for 12 months followed by zoledronate for 12 months.",[27],"Osteoporosis","RECRUITING","2026-07-01",{"date":31,"type":32},"2026-07-02","ACTUAL",{"date":34,"type":32},"2023-10-02",{"date":36,"type":21},"2032-08-31",{"name":38,"class":39},"University of Aarhus","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":40},"100645268","same-day-cochlear-implant-activation-sda-ci-100645268","NCT07681830","Same-Day Cochlear Implant Activation (SDA-CI)","Randomized Study of Same-Day Activation Versus Day-14 Activa- Tion in Adult Cochlear Implant Recipients","SDA-CI","Inclusion Criteria:\n\n* Age 18 years or older\n* Indication for cochlear implantation according to national guidelines\n* Ability to provide written informed consent\n\nExclusion Criteria: - Medical or surgical conditions rendering SDA unsuitable, including postoperative wound complications requiring pressure dressing, cognitive or communicative barriers precluding safe activation, or other clinical considerations (e.g. meningitis) assessed by the treating clinician.\n\n\\-","ALL","18 Years",{"count":52,"type":21},100,[54],"NA","This randomized controlled study investigates whether activating a cochlear implant on the day of surgery (same-day activation) leads to faster stabilization of cochlear implant programming compared with the current standard practice of activation approximately 14 days after surgery.\n\nAdult cochlear implant recipients at Aarhus University Hospital will be randomly assigned to either same-day activation or standard activation. The study will evaluate electrode impedance development, time to a stable cochlear implant map, changes in programming parameters, hearing outcomes, tinnitus, quality of life, rehabilitation progress, and safety.\n\nThe purpose of the study is to determine whether earlier activation can facilitate faster auditory rehabilitation and optimization of cochlear implant settings without increasing complications or patient discomfort.",[57,58],"Hearing Loss","Cochlear Implantation",[60,61,62,63,64,65],"Cochlear Implant","Same-Day Activation","Early Activation","Electrode Impedance","Stable Cochlear Implant Map","Cochlear Implant Mapping","NOT_YET_RECRUITING","2026-06-30",{"date":31,"type":32},{"date":70,"type":21},"2026-06-01",{"date":72,"type":21},"2029-12-01",{"name":38,"class":39},{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":49,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100428830","prosthesis-versus-active-exercise-program-in-patients-with-rotator-cuff-arthropathy-100428830","NCT04864158","Prosthesis Versus Active Exercise Program in Patients With Rotator Cuff Arthropathy","Prosthesis Versus Active Exercise Program in Patients With Rotator Cuff Arthropathy Eligible For Reverse Shoulder Arthroplasty: the ReAct Multicenter, Randomized Controlled Trial","REACT","Inclusion Criteria:\n\n* Patients 60-85 years\n* Eligible for RSA\n* Rotator cuff arthropathy according to Hamada grade 3, 4 and 5 (33)\n\nExclusion Criteria:\n\n* Previous shoulder fracture (fracture of the proximal humerus or glenoid fracture)\n* Planned other upper extremity surgery within six months\n* Rheumatoid arthritis or other types of arthritis not diagnosed as primary glenohumeral OA\n* Cancer diagnosis and receiving chemo-, immuno- or radiotherapy\n* Neurological diseases affecting shoulder mobility (e.g. disability after previous stroke, multiple sclerosis, Parkinson's, Alzheimer's disease)\n* Other reasons for exclusion (i.e. mentally unable to participate) or planned absence for more than 14 days in the first 3 months after baseline test.\n* Unable to communicate in the participating countries respective languages","60 Years","85 Years",{"count":85,"type":21},102,[54],"Reverse shoulder arthroplasty (RSA) is a well-established treatment for rotator cuff arthropathy. However, the effectiveness of RSA has not been compared to non-surgical treatment in a randomised controlled trial. Shoulder exercises may be an effective treatment for reducing pain and improving function in glenohumeral osteoarthritis. The primary aim of this trial is to examine if RSA followed by standard postsurgical rehabilitation is superior to a 12-week exercise programme in patients with rotator cuff arthropathy eligible for unilateral RSA. The investigators hypothesise that surgical intervention followed by standard rehabilitation, results in clinically relevant (14-point, on a scale from 0-100) improvement compared to the exercise intervention.",[89],"Rotator Cuff Arthropathy",[91,92,93,94,95,96],"Physiotherapist-supervised Exercise","Physical Therapy","Physical Rehabilitation","Reverse Shoulder Arthroplasty","Randomized Controlled Trial","Cuff Tear Arthropathy",{"date":31,"type":32},{"date":99,"type":32},"2021-05-28",{"date":101,"type":21},"2037-01",{"name":38,"class":39},8,{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},"100603259","fluorescence-guided-optimization-of-sarcoma-margins-100603259","NCT07134192","Fluorescence-Guided Optimization of Sarcoma Margins","FOCUS","Inclusion Criteria:\n\n* Biopsy verified intermediate-to-high grade sarcoma of theextremity or trunk wall\n* Age\\>18 years old\n* Tumor operable\n* Curative intent at time of surgery\n* Consent of patient\n\nExclusion Criteria:\n\n* History of allergic reaction to iodine-containing pharmaceuticals\n* End-stage renal disease or eGFR \\\u003C15\n* Patient decision\n* Lack of capacity\n* Inoperability",{"count":112,"type":21},90,[54],"This is a Danish national multicenter prospective cohort study to evaluate if fluorescence-guided surgery (FGS) using indocyanine green (ICG) can reduce the rate of positive margins following sarcoma resection.",[116,117],"Soft Tissue Sarcoma of the Trunk and Extremities","Sarcoma",[117,119,120,121,122,123,124],"ICG","Indocyanine green","Fluorescence Guided Surgery","FGS","STS","Soft Tissue Sarcoma","2026-06-29",{"date":29,"type":32},{"date":128,"type":32},"2025-09-01",{"date":130,"type":21},"2028-03-01",{"name":38,"class":39},2,{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":151,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":40},"100634333","wrist-injury-strengthening-exercise-wise-versus-usual-care-advice-for-improving-pain-and-function-100634333","NCT07538323","Wrist Injury Strengthening Exercise (WISE) Versus Usual Care Advice for Improving Pain and Function","Progressive Resistance and Flexibility Exercises Versus Usual Care Advice for Improving Pain and Function After Distal Radius Fracture in Adults Aged 50 Years or Over in Denmark: the WISE-DK Randomised Trial","WISE-DK","Inclusion Criteria:\n\n* Distal radius fracture treated surgically or non-surgically\n* Willing and able to give informed consent\n\nExclusion Criteria:\n\n* Injury is more than two months old\n* There is evidence that the patient would be unable to participate in therapy or a self-guided exercise program provided by a participating center or adhere to study procedures (including cognitive impairment and fracture\u002Fsurgery complications such as Complex Regional Pain Syndrome)\n* No e-mail address to receive electronic questionnaires\n* Open fractures with a Gustilo \\& Anderson grading \\>1",{"count":142,"type":21},588,[54],"The goal of this clinical trial is to find out whether a therapist-guided exercise program helps people aged 50 and older recover better, in terms of pain and function, after a wrist fracture, compared to the usual care advice they would normally receive. The main question it aims to answer is:\n\n• Will participants who receive a therapist-supervised exercise program have better improvement in pain and function, as measured by the Patient Rated Wrist Evaluation questionnaire, six months after their injury?\n\nResearchers will compare these participants with those who receive usual care, which includes advice on self-management, to see if the supervised exercise program leads to greater recovery.\n\nParticipants will:\n\n* Either receive supervised exercise, with a therapy session of up to 60 minutes and two additional sessions of up to 30 minutes each in addition to usual-care, or they will receive solely usual-care, consisting of advice on self-management.\n* Complete questionnaires electronically at baseline, 3-months, and 6-months.",[146,147,148,149,150],"Distal Radius Fracture","Colles Fracture","Wrist Fracture","Wrist Fractures","Fracture Arm",[152,153,154,155],"Exercise","Therapy","Resistance training","Strengthening exercise","2026-06-26",{"date":67,"type":32},{"date":159,"type":32},"2026-05-12",{"date":161,"type":21},"2029-12",{"name":38,"class":39},{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":171,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":175,"conditions":176,"keywords":180,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":191},"100408852","when-to-induce-for-overweight-window-100408852","NCT04603859","When to INDuce for OverWeight? (WINDOW)","When to INDuce for OverWeight? - a Randomised Controlled Trial (WINDOW)","WINDOW","Inclusion Criteria:\n\n• Pregnant women with pre- or early pregnancy BMI ≥ 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Legal or ethical considerations: maternal age \\\u003C18 years, language difficulties requiring an interpreter or translator\n* Multiple pregnancy\n* Previous caesarean section\n* Uncertain gestational age, defined as gestational age determined by other measurements than the Crown-Rump length (CRL) Measurement\n* Planned elective caesarean section at time of randomisation\n* Fetal contraindications to IOL at time of randomisation: e.g. non-cephalic presentation, or other fetal conditions contraindicating vaginal delivery\n* Fetal contraindications to expectant management at time of randomisation\n* Maternal contraindications to IOL at time of randomisation: e.g. placenta previa\u002Faccreta, vasa previa\n* Maternal contraindications to expectant management at time of randomisation: e.g. maternal medical conditions, ultrasonically diagnosed oligohydramnios (DVP\\\u003C 2 cm), signs of labour including pre-labour rupture of membranes (PROM)",true,{"count":173,"type":21},1900,[54],"The rate of overweight and obese women becoming pregnant is increasing. Obesity in pregnancy along with delivery by cesarean section in obese women is associated with several complications as compared to normal weight women. The longer the woman is pregnant, the longer she is at risk. In an otherwise low-risk pregnant woman at term, it is an ongoing clinical dilemma, whether the benefits of elective induction of labor and termination of the pregnancy will outweigh the potential harms from concomitant induction and delivery process. The proposed study is a randomized controlled study of elective induction versus expectant management in obese women. The study will be carried out as a national multicenter study with inclusion of 1900 participants from Danish delivery wards. The null hypothesis is that the caesarean section rate is similar with elective induction of labor at 39 weeks of gestation, compared with expectant management among pregnant women with pre- or early pregnancy BMI≥30.",[177,178,179],"Pregnancy","Obesity","Parturition",[181,182,183],"Induction of labor","Expectant management","Cesarean section","2026-06-22",{"date":156,"type":32},{"date":187,"type":32},"2020-10-19",{"date":189,"type":21},"2026-07",{"name":38,"class":39},12,{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":12,"sex":49,"minAge":199,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":209,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":226},"100642134","phase-4-ironcare-iron-treatment-in-older-patients-with-hip-fractures-100642134","NCT07659184","IRONCARE: Iron Treatment in Older Patients With Hip Fractures","IRONCARE: Iron Treatment in Older Patients With Hip Fractures - A Double-blinded Placebo-controlled Randomized Trial","Inclusion Criteria:\n\n* Hip fracture (ICD-10 codes: DS720, DS721 and DS722)\n* Low energy trauma\n* Age ≥ 75 years\n* Hemoglobin ≤7.0 mmol\u002FL (11 g\u002FdL) during hospital admission\n\nExclusion Criteria:\n\n* Pathological fracture\n* Periprosthetic fracture\n* Inability to understand or speak Danish\n* Dysphagia and thus inability to swallow study medication\n* Signs of iron overload, hemochromatosis, or hemosiderosis\n* Liver disease (cirrhosis or hepatitis) and transaminase levels \\>3 times upper limit of normal\n* Known allergy to iron formulations\n* Severe asthma\n* Severe hypophosphatemia: \\\u003C0.35 mmol\u002FL\n* Patients already receiving iron supplementation that cannot be paused for the study period\n* Cognitive impairment that results in either memantine-treatment or a Short Portable Mental Status Questionnaire (SPMSQ) score \\> 4","75 Years",{"count":201,"type":21},528,[24],"The aim of this study is to investigate the effects of intravenous (IV) iron therapy compared to alternate-day oral iron treatment and no supplementation in older patients with hip fractures. This study will examine the impact of iron treatment on fatigue, functional decline, fear of falling, cognitive impairment, and quality of life, as well as its effects on iron stores and hemoglobin levels, with the overall goal of improving postoperative rehabilitation.\n\nThe trial will be conducted on five different hospitals in the Central Region of Denmark (Region Midtjylland).",[205,206,207,208],"Hip Fracture","Anemia","Iron","Placebo - Control",[210,206,211,212,213,214,215,216,217],"Hip fracture","iron","Intravenous iron","mobility","fatigue","hemoglobin","RCT","Placebo","2026-06-19",{"date":220,"type":32},"2026-06-24",{"date":222,"type":21},"2026-10-01",{"date":224,"type":21},"2028-09-30",{"name":38,"class":39},5,{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":238,"conditions":239,"keywords":241,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":40},"100611967","transthoracic-drainage-of-lung-abscesses-a-national-randomized-trial-100611967","NCT07247461","Transthoracic Drainage of Lung Abscesses. A National Randomized Trial.","TOLA: Transthoracic Drainage of Lung Abscesses. A National Randomized Trial","TOLA","Inclusion Criteria:\n\n* Age \\>18 years.\n* Signed informed consent.\n* CT scan compatible with LA (one or more cavitating lesions with liquid content).\n* Clinical findings suggestive of ongoing infection.\n* Lung abscess size ≥ 4 cm in diameter.\n* Imaging indicates that the abscess contains fluid.\n* The abscess involves the outer one-third of the lung.\n\nExclusion Criteria:\n\n* Pregnancy. Prior to inclusion of fertile women, a negative pregnancy test must be available.\n* Brest feeding.\n* Predicted survival of less than 3 months.\n* Known tuberculosis or non-tuberculous mycobacteriosis.\n* Known chronic pulmonary aspergillosis.\n* Patients with a primary suspicion of lung cancer\n* Recent (\\\u003C3 months) contact with health facilities outside Scandinavia.\n* Patients in whom anticoagulant treatment cannot be discontinued, or in whom the treatment pause does not allow drainage within 72 hours.\n* Coagulopathy or other increased bleeding risk that cannot be corrected to allow drainage within 72 hours.\n* Hemodynamic and\u002For respiratory unstable patient.",{"count":236,"type":21},84,[54],"This study aims to investigate if early drainage of lung abscesses, in addition to standard antibiotic treatment, leads to shorter length of hospital stay.\n\nStudy Design\n\nThis is a randomized, controlled clinical trial. That means participants will be randomly assigned to one of two groups:\n\n1. Drainage group: Receives a chest tube (drain) inserted through the chest wall into the abscess in combination with standard intravenous antibiotics.\n2. Control group: Receives standard intravenous antibiotics only\n\nEach participant has a 50\u002F50 chance of being placed in either group.\n\nDuring Hospital Stay All participants will begin treatment with intravenous antibiotics (piperacillin\u002Ftazobactam). If assigned to the drainage group, a trained medical team will insert a small tube into the abscess to drain the pus. The tube is flushed three times a day with sterile saline.\n\nParticipants will also:\n\n* Fill out two short health questionnaires at the start and during follow-up.\n* Have relevant medical history collected from their hospital records.\n* Undergo routine scans (CT), blood tests, and lung assessments as part of standard care.\n* A cheek swab will be taken from all participants to study mouth bacteria..\n\nFor those receiving drainage the pus from the lung abscess will be collected for microbiological analysis.\n\nMicrobiology samples will be stored in a research biobank and destroyed after analysis.\n\nFollow-up after discharge\n\n* 1 week: A phone call to check symptoms and infection levels via a blood test.\n* 4 and 12 weeks later: In-person checkups at the lung clinic, including:\n\n  * 6-minute walk test\n  * Lung function test\n  * Repeat health questionnaires\n  * CT scan\n  * Blood tests (up to 20 ml in total over the study)\n* 1 years: Medical records are reviewed to asses morbidity and mortality.\n\nParticipants The study will include 84 adult patients who are hospitalized with a lung abscess larger than 4 cm, located near the outer part of the lung. Inclusion will take place at five university hospitals in Denmark\n\nWhy This Study Matters There are no official guidelines for treating lung abscesses, and research is limited. This study could offer vital new insights that help update treatment recommendations in Denmark and internationally.\n\nBecause all five Danish regions are involved, the results could quickly be implemented into daily practice, improving care for future patients with this serious condition.",[240],"Lung Abscess",[240,242,243,244],"Transthoracic drainage","Length of hospital stay","Randomized trial","2026-06-09",{"date":247,"type":32},"2026-06-10",{"date":249,"type":32},"2026-02-16",{"date":251,"type":21},"2029-08-30",{"name":38,"class":39},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":22,"phases":262,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":273,"completionDateStruct":274,"leadSponsor":276,"locationsCount":40},"100643012","individualized-exercise-consultation-in-type-1-diabetes-100643012","NCT07596160","Individualized Exercise Consultation in Type 1 Diabetes","ACTIVE-T1D","Inclusion Criteria:\n\n* Diagnosis of type 1 diabetes\n* Age ≥18 years\n* Willingness to participate\n\nExclusion Criteria:\n\n* None",{"count":261,"type":21},60,[54],"People with type 1 diabetes often experience challenges managing blood glucose levels during and around physical activity, which may reduce participation in exercise. The ACTIVE-T1D project aims to evaluate whether individualized video-based exercise consultations can improve exercise-related confidence, physical activity levels, and glycemic management in adults with type 1 diabetes. Participants will receive individualized consultations focused on exercise, glucose management, insulin adjustment, and nutrition strategies related to physical activity. Consultations are tailored to the participant's exercise habits, goals, and challenges. The study will assess self-reported exercise management, physical activity, and glucose metrics obtained from continuous glucose monitoring systems. A subgroup of participants will also complete objective physical activity measurements using accelerometers. The study is conducted as a prospective quality improvement project at Steno Diabetes Center Aarhus.",[265],"Type 1 Diabetes",[267,268,269,270],"exercise","type 1 diabetes","intervention","consultations","2026-06-05",{"date":245,"type":32},{"date":70,"type":21},{"date":275,"type":21},"2028-06-01",{"name":38,"class":39},{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":4},"100643717","internet-delivered-psychological-treatment-of-functional-gastrointestinal-disorders-100643717","NCT07636122","Internet-delivered Psychological Treatment of Functional Gastrointestinal Disorders","Internet-delivered Psychological Treatment of Functional Gastrointestinal Disorders - A Danish Feasibility Study","Inclusion Criteria:\n\n1. Age ≥ 18.\n2. A primary diagnosis of functional disorders, gastrointestinal, specifically irritable bowel syndrome operationalized by ROME IV (DR58)\n3. Normal recommended routine medical investigations: growth, blood samples including TSH, total IgA, IgA-tissue transglutaminase, complete blood count, erythrocyte sedimentation rate and C-reactive protein analysis, liver enzymes and fecal calprotectin.\n4. Refractory gastrointestinal functional symptoms despite medical treatment (in accordance with guidelines)\n5. Stable dosage of FGID-related medication such as laxatives, Imodium or pain-modulating psychopharmacological medication during the past month.\n6. Living in Denmark.\n7. Access to a computer or tablet with an internet connection.\n\n   \\-\n\nExclusion Criteria:\n\n1. \\- Another disease that explains the symptoms.\n2. Chronic inflammatory bowel disease (e.g., Crohns, colitis ulcerosa).\n3. Lactose intolerance, celiac disease, and food allergies, in accordance with guidelines.\n4. Severe psychiatric problems (e.g., suicidal ideation, depression).\n5. Insufficient language or computer skills.\n6. Addiction to alcohol, drugs or medicine.\n7. Treatment with opioids or other addictive drugs such as benzodiazepines\n8. Lactose-\u002Fgluten-intolerance where the diet has not been adjusted accordingly.\n9. Severe cognitive or intellectual dysfunction or diagnosed autism spectrum disorder, which prevent the participant from interaction with the program\n10. Ongoing psychological treatment.",{"count":285,"type":21},30,[54],"Brief Summary\n\nFunctional gastrointestinal disorders (FGID), including irritable bowel syndrome (IBS), are common conditions characterized by recurrent gastrointestinal symptoms that cannot be fully explained by structural disease. FGID are associated with reduced quality of life, functional impairment, psychiatric comorbidity, and high healthcare utilization. Psychological interventions, particularly cognitive behavioral therapy (CBT), have demonstrated beneficial effects in FGID, but access to specialized treatment remains limited.\n\nThis study aims to evaluate the feasibility, acceptability, and potential clinical effects of a Danish exposure-based internet-delivered cognitive behavioral therapy (iCBT) program for adults with FGID. The intervention has been translated and culturally adapted from a Swedish program with previously documented efficacy.\n\nIn this single-arm feasibility study, 30 adults with FGID will complete a 10-week therapist-supported iCBT program consisting of psychoeducation, symptom monitoring, identification of avoidance behaviors, exposure exercises, and relapse prevention strategies. Participants will receive asynchronous weekly written support from trained CBT therapists.\n\nFeasibility outcomes include treatment adherence and completion, participant satisfaction, treatment credibility, working alliance, adverse effects, and acceptability of the internet platform. Clinical outcomes include gastrointestinal symptom severity and quality of life, alongside measures of illness perceptions, illness worry, emotional distress, behavioral responses, functional symptoms, and spontaneous cognition during rest. Assessments will be conducted at baseline, post-treatment, and 3-month follow-up.\n\nThe study is conducted in Denmark as part of The Danish FGID Treatment Study through collaboration between Aarhus University Hospital, Regional Hospital Silkeborg, Aarhus University, and Karolinska Institute, Sweden. The findings will inform the future implementation and evaluation of internet-delivered psychological treatment for Danish patients with FGID.",[289],"Functional Gastrointestinal Disorders (FGID)","2026-06-04",{"date":245,"type":32},{"date":293,"type":21},"2026-05-30",{"date":295,"type":21},"2027-12-20",{"name":38,"class":39},{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":49,"minAge":304,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":310,"conditions":311,"keywords":313,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":226},"100558448","phase-3-efficacy-of-solifenacin-mirabegron-and-combination-therapy-in-children-with-daytime-urinary-incontinence-bedry-100558448","NCT06551246","Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)","Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Overactive Bladder and Daytime Urinary Incontinence (BeDry)","Inclusion Criteria:\n\n1. The participants custody holder(s) must voluntarily sign and date an informed consent prior to initiation of any study specific procedures.\n2. Age 5 to 14 years (inclusive) at the time of inclusion.\n3. Overactive bladder as per International Children's Continence Society criteria\n4. At least 2 daytime urinary incontinence episodes per week\n5. Inadequate effect of at least 4 weeks urotherapy (non-pharmacological treatment)\n6. No previous treatment with solifenacin, mirabegron or bladder\u002Fsphincter botulinum toxin injections\n7. No current constipation as per ROME IV criteria or fecal incontinence (laxative treatment is accepted)\n8. Per investigator's judgment, the participant can swallow or can learn to swallow study medication\n\nExclusion Criteria:\n\n1. Inability of the patent(s) or legal guardian(s) to understand the Danish written and oral information\n2. Known or suspected hypersensitivity to study medication\n3. Any contraindication to the use of the study medication\n4. Known urogenital anatomical abnormalities affecting lower urinary tract function\n5. Known kidney or bladder stones\n6. Known diabetes insipidus\n7. Ongoing symptomatic urinary tract infection\n8. Recurrent urinary tract infection or ongoing prophylactic antibiotic treatment\n9. Known QTc prolongation, QTc \\>460 ms, or risk of QTc prolongation (hypokalaemia, exercise-induced syncope, or familial long QT syndrome)\n10. Other significant electrocardiogram abnormalities\n11. Known hypertension\n12. ≤3 daily voiding, evaluated by 48-hour frequency-volume chart\n13. Uroflowmetry suggestive of other pathology than overactive bladder (staccato-shaped, interrupted-shaped, or plateau-shaped curve)\n14. Post-void residual \\>50 ml after double voiding\n15. Dipstick haematuria (≥2+ erythrocytes) or macroscopic haematuria\n16. Pregnancy or breastfeeding\n17. Female subjects of childbearing potential\n18. Ongoing constipation according to Rome IV-criteria which is intractable to medication or fecal incontinence\n19. Inability to swallow study medication\n20. Use of any medication during study period, except permitted medication","5 Years","14 Years",{"count":307,"type":21},236,[309],"PHASE3","The primary objective is to evaluate if (1) combination therapy of solifenacin and mirabegron in low doses is superior to monotherapy of solifenacin in high dose and if (2) combination therapy of mirabegron and solifenacin in low doses is superior to monotherapy of mirabegron in high dose in treatment of daytime urinary incontinence among children aged 5 to 14 years who are none complete responders to respectively monotherapy of solifenacin in low dose or monotherapy of mirabegron in low dose.\n\nIn total, 236 children diagnosed with daytime urinary incontinence will be randomized 1:1:1:1 to one of four treatment groups. Total pharmacological treatment period will be 18 weeks.",[312],"Urinary Incontinence in Children",[314,315,316,317,318,319],"Urinary incontinence","Daytime urinary incontinence","Overactive bladder","Children","Solifenacin","Mirabegron",{"date":321,"type":32},"2026-06-08",{"date":323,"type":32},"2024-06-27",{"date":325,"type":21},"2027-12-01",{"name":38,"class":39},{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":49,"minAge":18,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":337,"phases":4,"briefSummary":338,"conditions":339,"keywords":341,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":354},"100635434","disease-activity-monitoring-in-patients-with-giant-cell-arteritis-study-100635434","NCT07552636","Disease Activity Monitoring in Patients With Giant Cell Arteritis Study","Disease Activity Monitoring in Patients With Giant Cell Arteritis","DiAcMo","Inclusion Criteria:\n\n1. Clinical GCA diagnosis established\u002Fconfirmed by a rheumatologist and positive GCA imaging or biopsy at diagnosis \\\u003C 3 years.\n2. Clinical remission at the time of inclusion, defined as\n\n   * Having adhered for ≥ 8 weeks prior to inclusion to either (a) the planned tapering of glucocorticoid therapy, or (b) the planned glucocorticoid-sparing DMARD treatment (with or without glucocorticoids).\n   * Absence of, or no worsening of, symptoms attributed to GCA in ≥ 8 weeks.\n   * Normal CRP level (\\\u003C 10 mg\u002FL) within 7 days before inclusion.\n3. Current prednisolone dosage of ≥ 5 mg if glucocorticoid monotherapy.\n4. A continuous tapering of monotherapy or combination therapy is planned.\n5. Age \\> 50 years.\n6. Study participants must be able to speak and understand spoken and written Danish.\n\nExclusion Criteria:\n\n1. Intra-articular, intravenous or intramuscular glucocorticoid ≤ 7 weeks prior to inclusion.\n2. Study participants who are unable to complete online questionnaires cannot participate in the GCA-PRO component of the study.\n3. Presence of cognitive impairment, including clinically significant dementia, that may interfere with the ability to provide informed consent or comply with study procedures.",{"count":336,"type":21},175,"OBSERVATIONAL","Giant Cell Arteritis (GCA) is a vasculitis of medium- and large-sized arteries in older adults that may lead to serious vascular complications, including permanent vision loss and aortic aneurysm formation. Glucocorticoids are effective, but relapse during tapering is common and poses a major clinical challenge, potentially contributing to prolonged glucocorticoid exposure. Symptoms are often nonspecific and conventional inflammatory markers lack sufficient reliability, particularly in patients treated with drugs targeting the interleukin-6 pathway. Thus, this project aims to evaluate different tools assisting disease activity monitoring and\u002For predict future relapses and higher treatment requirements. Up to 175 patients with GCA in remission will be enrolled to ensure that 144 participants complete 1 year of follow-up. Participants undergo vascular ultrasonography, including double-blinded assessment at suspected relapse, complete patient-reported outcome measures, and provide biobank blood samples.",[340],"Giant Cell Arteritis (GCA)",[342,343,344,345],"vascular ultrasonography","disease activity monitoring","giant cell arteritis","patient-reported outcome measures","2026-05-27",{"date":348,"type":32},"2026-05-29",{"date":350,"type":32},"2026-05-06",{"date":352,"type":21},"2029-02",{"name":38,"class":39},7,{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":363,"targetDuration":364,"studyType":337,"phases":4,"briefSummary":365,"conditions":366,"keywords":374,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":384},"100633844","vascular-complications-after-kidney-transplantation-100633844","NCT07531966","Vascular Complications After Kidney Transplantation","Vascular Complications After Kidney Transplantation: A Prospective National Multicenter Study - The DAN-PTRAIII Study","DAN-PTRAIII","Inclusion Criteria:\n\n1\\. At least one of the following clinical criteria (1 or 2) must be fulfilled:\n\n1. Graft dysfunction, defined by at least one of the following:\n\n   * Acute reduction in estimated glomerular filtration rate (eGFR) \\>15% on two consecutive measurements at least 2 weeks apart, with other causes excluded (rejection, obstruction, infection).\n   * eGFR \\\u003C50% of the expected value 30 days after kidney transplantation of unknown cause.\n   * Decline in eGFR \\>30% after initiation of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.\n2. Persistent resistant hypertension for more than 6 weeks after kidney transplantation, defined as:\n\n   * 24-hour ambulatory systolic blood pressure \\>130 mmHg despite treatment with at least three classes of antihypertensive medication at maximally tolerated doses (including diuretics, if tolerated).\n\nTogether with at least one of the following radiological criteria:\n\n1. CT or MR angiography demonstrating a lumen reduction ≥50%.\n2. Doppler ultrasound showing:\n\n   1. Peak systolic velocity in the renal artery ≥200 cm\u002Fs and a renal renal ratio (velocity at stenosis \u002F velocity in distal artery) \\>4.\n   2. Acceleration time \\>70 ms in intrarenal arteries.\n\n2\\. In cases of strong clinical suspicion of a vascular complication where CT or MR angiography cannot reliably exclude graft artery or vein stenosis, patients may be referred for confirmatory invasive investigations.\n\nBefore PTA, catheter-based angiography and translesional pressure measurements are performed to confirm whether the patient meets the radiological eligibility criterion for PTA:\n\n1. Stenosis ≥70%.\n2. Stenosis 50-69% if at least one of the following criteria is met:\n\n   * Mean translesional pressure gradient ≥10 mmHg.\n   * Systolic pressure gradient ≥20 mmHg.\n   * Renal Pd\u002FPa ≤0.8.\n   * If pressure measurements cannot be obtained, treatment is based on the operator's clinical judgement.\n\nExclusion Criteria:\n\n1. Inability to provide informed consent.\n2. Concurrent biopsy demonstrating rejection requiring treatment.\n3. Pregnancy.\n4. Previous PTA of the same vessel.\n5. Patients unable to tolerate any form of antithrombotic therapy and therefore not eligible for stent placement.",{"count":261,"type":21},"10 Years","* To determine the incidence of arterial inflow problems and venous outflow problems as causes of impaired renal function and\u002For treatment-resistant hypertension after kidney transplantation, when all kidney-transplant recipients in Denmark are evaluated according to uniform, well-defined clinical criteria.\n* To investigate the efficacy and safety of catheter-based balloon treatment (percutaneous transluminal angioplasty, PTA) for these vascular complications, of which transplant renal artery stenosis is by far the most common.\n* To assess whether novel imaging and functional diagnostic methods can predict treatment response.",[367,368,369,370,371,372,373],"Kidney Transplant Recipient","Kidney Transplant; Complications","Transplant Renal Artery Stenosis","Renovascular Disease","Renal Transplant Graft Failure","Renovascular Hypertension","Heart Failure",[368,369,375,376],"renovascular disease","Percutaneous transluminal angioplasty","2026-05-26",{"date":346,"type":32},{"date":380,"type":32},"2026-05-22",{"date":382,"type":21},"2031-06-01",{"name":38,"class":39},3,{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":171,"sex":17,"minAge":393,"maxAge":394,"enrollmentInfo":395,"targetDuration":4,"studyType":22,"phases":397,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":403,"completionDateStruct":404,"leadSponsor":406,"locationsCount":40},"100617344","investigating-the-effects-of-intermittent-hypoxia-hyperoxia-treatment-ihht-in-people-with-myalgic-encephalomyelitischronic-fatigue-syndrome-mecfs-to-improve-fatigue-pain-and-quality-of-life-by-targeting-mitochondrial-dysfunction-and-autonomic-nervous-system-impairment-100617344","NCT07317401","Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome (ME\u002FCFS) to Improve Fatigue, Pain, and Quality of Life by Targeting Mitochondrial Dysfunction and Autonomic Nervous System Impairment","REenergizeME: Oxygen Therapy (OT) as a Novel Treatment for Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome (ME\u002FCFS)","REenergizeME","ME\u002FCFS Patients\n\nInclusion Criteria:\n\n* Female sex\n* Age 20-59 years\n* Established diagnosis of Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome (ME\u002FCFS) according to the International Consensus Criteria (ICC)\n* Disease duration \\>6 months\n* Presence of post-exertional malaise (PEM)\n* Mild or moderate disease severity according to NICE guidelines\n* Body mass index (BMI) \\>18 and \\\u003C30 kg\u002Fm²\n* Ability and willingness to attend study visits and complete the intervention protocol\n* Provision of written informed consent\n* Willingness to comply with all study procedures and restrictions throughout the study period\n* Use of highly effective contraception during study participation for women of childbearing potential\n\nExclusion Criteria:\n\n* Severe ME\u002FCFS according to NICE guidelines\n* Participation in another clinical trial that may interfere with the present study\n* Pregnancy, planned pregnancy, or breastfeeding\n* Presence of clinically significant psychiatric disease not considered part of ME\u002FCFS and likely to interfere with study participation or interpretation of results\n* Presence of clinically significant neurological disease, peripheral nerve disorder, or other neurological dysfunction not considered part of ME\u002FCFS\n* Active internal disease or clinically significant cardiovascular, pulmonary, metabolic, renal, hepatic, endocrine, or systemic disease that may interfere with study participation or interpretation of outcomes\n* Obstructive lung disease\n* Claustrophobia\n* History of spontaneous pneumothorax\n* Presence of implanted medical devices, prostheses, or other conditions considered incompatible with IHHT\n* Chronic pain conditions not considered part of ME\u002FCFS and likely to interfere with assessments\n* Current structured graded exercise therapy (GET) or structured exercise programme\n* Significant alcohol, tobacco, or cannabis use considered likely to interfere with study participation or interpretation of outcomes\n* Inability to comply with study procedures or communicate meaningfully with study personnel\n* Any condition which, in the opinion of the investigator, may compromise participant safety or study integrity\n\nHealthy Controls\n\nInclusion Criteria:\n\n* Female sex\n* Age 20-59 years\n* Body mass index (BMI) \\>18 and \\\u003C30 kg\u002Fm²\n* Ability and willingness to attend study visits\n* Provision of written informed consent\n* Good general health without clinically significant chronic medical, neurological, psychiatric, or pain conditions\n* Activity level and BMI broadly matched to ME\u002FCFS participants\n* Willingness to comply with all study procedures and restrictions throughout the study period\n* Use of highly effective contraception during study participation for women of childbearing potential\n\nExclusion Criteria:\n\n* Current or previous diagnosis of ME\u002FCFS\n* Participation in another clinical trial that may interfere with the present study\n* Pregnancy, planned pregnancy, or breastfeeding\n* Presence of clinically significant psychiatric, neurological, cardiovascular, pulmonary, metabolic, renal, hepatic, endocrine, or systemic disease\n* Chronic pain conditions, migraine disorder, or recurrent headache\u002Fback pain likely to interfere with study assessments\n* Obstructive lung disease\n* Claustrophobia\n* History of spontaneous pneumothorax\n* Presence of implanted medical devices, prostheses, or other conditions considered incompatible with study procedures\n* Current structured exercise programme or recent major change in exercise habits\n* Significant alcohol, tobacco, or cannabis use considered likely to interfere with study participation or interpretation of outcomes\n* Inability to comply with study procedures or communicate meaningfully with study personnel\n* Any condition which, in the opinion of the investigator, may compromise participant safety or study integrity","20 Years","59 Years",{"count":396,"type":21},104,[54],"This study is testing a new treatment for people with Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome (ME\u002FCFS) and long-term symptoms after COVID-19. Both conditions cause extreme fatigue, muscle pain, \"brain fog,\" and trouble concentrating, which often get worse after physical or mental activity. Currently, no effective treatments are available.\n\nThe treatment being studied is called Intermittent Hypoxia-Hyperoxia Treatment (IHHT). It uses a machine called HypoxBreath to deliver short cycles of low oxygen (hypoxia) and high oxygen (hyperoxia) through a mask. Each session lasts 22-40 minutes and is carefully monitored to track oxygen levels, heart rate, and breathing. The therapy is customized for each patient to ensure comfort and effectiveness. IHHT is believed to help the body adapt to oxygen-related stress, improving energy production and reducing inflammation.\n\nIn this trial, 104 patients with ME\u002FCFS will be randomly assigned to receive either IHHT or a placebo treatment with normal oxygen levels over eight weeks. The placebo group will follow a similar procedure without oxygen changes. An additional 20 healthy individuals will be recruited as a comparison group, but they will not undergo the treatment.\n\nParticipants will have medical check-ups before and after treatment to evaluate changes in fatigue, mental sharpness, pain, autonomic nervous system function, and overall quality of life. Blood samples and small skin biopsies will also be taken to study the biological processes behind ME\u002FCFS and how the treatment works.\n\nThis research aims to find out if IHHT can improve the lives of people with ME\u002FCFS or long-term COVID symptoms. The results could also provide new insights into the causes of these challenging conditions and guide future treatments.",[400],"Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome (ME\u002FCFS) (ICD-10 G93.3)","2026-05-20",{"date":380,"type":32},{"date":70,"type":21},{"date":405,"type":21},"2029-01-01",{"name":38,"class":39},{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":49,"minAge":199,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":22,"phases":416,"briefSummary":417,"conditions":418,"keywords":421,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":132},"100588237","how-bleeding-affects-delirium-in-older-patients-with-hip-fractures-the-improve-hip-study-100588237","NCT06938789","How Bleeding Affects Delirium in Older Patients With Hip Fractures: The IMPROVE-HIP Study","The Impact of Bleeding on Delirium Outcomes in Older Patients With Hip Fractures: A Single-Blind, Randomized Controlled Trial - The IMPROVE-HIP Study","Inclusion Criteria:\n\n* Hip fracture\n\nExclusion Criteria:\n\n* Pathological hip fracture\n* Periprosthtic fracture\n* Unable to speak or understand Danish\n* Does not wish to recieve blood transfusion\n* If the investigator finds the patient unable to cooperate to the study (e.g. in case of severe dementia and externalizing behaviour)",{"count":415,"type":21},198,[54],"The goal of this clinical trial is to investigate whether early detection of bleeding and prompt blood transfusions can help prevent delirium in patients aged 75 and older who are admitted to the hospital with hip fractures. The main question the trial aims to answer is:\n\nDo patients aged 75 and older with hip fractures benefit from earlier treatment of anemia (low blood count) to reduce the risk of delirium?\n\nResearchers will compare early diagnosis and treatment of bleeding with standard care to determine if it helps lower the risk of developing delirium.\n\nParticipants will:\n\nUndergo blood tests, have their vital signs monitored, and be screened for delirium three times a day for the first 48 hours after surgery.\n\nReceive blood transfusions promptly if their hemoglobin levels fall below a specified threshold.\n\nAttend a follow-up visit at 30 days to assess cognitive function and overall quality of life.\n\nAttend another follow-up at 90 days to evaluate hospital readmissions and survival.",[419,205,420],"Bleeding","Delirium - Postoperative",[210,422,423],"Delirium","Blood transfusion","2026-05-19",{"date":380,"type":32},{"date":427,"type":32},"2025-04-24",{"date":429,"type":21},"2027-06-01",{"name":38,"class":39},{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":437,"enrollmentInfo":438,"targetDuration":4,"studyType":22,"phases":439,"briefSummary":440,"conditions":441,"keywords":446,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":132},"100598439","new-methods-for-evaluating-preventive-migraine-treatment-100598439","NCT07071506","New Methods for Evaluating Preventive Migraine Treatment","Inclusion Criteria:\n\n1. Adults (18-65 years)\n2. ≥ 1-year history of migraine with or without aura according to the International Classification of Headache Disorders (ICHD-3) diagnostic criteria\n3. Known chronic migraine (headache occurring ≥ 15 days per month for \\> 3 months, which on at least 8 days per month has the features of migraine headache) diagnosed before age 65\n4. Eligibility for preventive migraine treatment\n5. Ability to speak and read Danish\n\nExclusion Criteria:\n\n1. Use of onabotulinumtoxinA as preventive migraine treatment during the 4 months before inclusion\n2. Use of other preventive migraine treatment except CGRP antagonists (However, participants are allowed to be on two stable preventive medication (antidepressant, calcium channel blockers, beta blockers or antiepileptic)- 2 months prior to inclusion until end of study), devices for migraine prevention such as transcranial magnetic stimulation and use of nerve blocks 3 months prior to inclusion\n3. Use of opioid or barbiturate medications in the last four weeks before inclusion\n4. Secondary headache disorders including medication overuse headache\n5. Severe psychiatric, vascular disease, or known liver disease\n6. Alcohol abuse or substance abuse\n7. Current or planned pregnancy and lactation","65 Years",{"count":261,"type":21},[54],"The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided. Using a clinical within-subjects, balanced placebo design, patients with chronic migraine will receive four treatment conditions in a randomized order.",[442,443,444,445],"Migraine","Migraine With or Without Aura","Headache Disorders","Chronic Migraine, Headache",[447,448,449,450,451],"Headache","Chronic migraine","Balanced placebo design","Treatment effects","Adverse events","2026-05-18",{"date":424,"type":32},{"date":455,"type":32},"2025-06-19",{"date":457,"type":21},"2028-09",{"name":38,"class":39},{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":466,"targetDuration":468,"studyType":337,"phases":4,"briefSummary":469,"conditions":470,"keywords":472,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":384},"100623761","evaluation-of-dna-methylation-markers-for-endometrial-cancer-risk-stratification-using-patient-collected-urine-and-vaginal-samples-and-clinician-collected-cervical-samples-from-women-with-postmenopausal-bleeding-100623761","NCT07400835","Evaluation of DNA Methylation Markers for Endometrial Cancer Risk-stratification Using Patient-collected Urine and Vaginal Samples and Clinician-collected Cervical Samples From Women With Postmenopausal Bleeding","The ENDOMETRIAL Study: EvaluatioN of DNA methylatiOn Markers for EndomeTrial Cancer Risk-stratification Using Patient-collected urIne and vAginal Samples and Clinician-collected Cervical Samples From Women With Postmenopausal bLeeding","Inclusion Criteria:\n\n* Postmenopausal bleeding (defined as vaginal bleeding after absence of periods for ≥ 12 months) undergoing diagnostic evaluation for EC at gynaecological departments\n* Treated in Central Denmark Region or Southern Denmark Region, Denmark\n* Able to provide written consent for participation\n* Able to read and understand Danish\n\nExclusion Criteria:\n\n* Other concurrent cancer diagnosis besides diagnostic evaluation for postmenopausal bleeding\n* Withdrawal of consent\n* Hysterectomized",{"count":467,"type":21},600,"2 Years","The goal of this observational study is to investigate the clinical utility of DNA-methylation testing in urine and vaginal samples collected by patients and cervical samples collected by clinicians, to determine the risk of endometrial cancer in symptomatic women with postmenopausal bleeding. The study aims to answer the following research questions:\n\n* What is the diagnostic accuracy of DNA methylation testing in urine, vaginal and cervical samples compared to traditional TVUS for endometrial cancer detection?\n* What is the 2-year risk of EC among women testing negative on TVUS and\u002For DNA methylation tests or those testing positive on methylation only?\n\nResearchers will compare DNA methylation testing in patient-collected urine and vaginal samples as well as in clinician-collected cervical samples, with the traditional diagnostic pathway for women with PMB, which includes TVUS evaluation, and when indicated by abnormal TVUS findings, endometrial biopsy according to clinical guidelines.\n\nParticipants will\n\n* take a urine and vaginal sample\n* have a cervical sample collected by a clinician\n* undergo TVUS evaluation according to clinical guidelines\n* If TVUS shows thickened endometrium (≥ 5 mm) and\u002For irregularity, an endometrial biopsy will be collected according to clinical guidelines\n* fill out a questionnaire regarding acceptability and preferences of sampling methods and complete a lifestyle questionnaire.",[471],"Postmenopausal Bleeding",[473,474,475,476,477,478],"DNA methylation","Postmenopausal bleeding","Endometrial Cancer","Patient-collected urine samples","cervical samples","Patient-collected vaginal samples",{"date":480,"type":32},"2026-05-13",{"date":482,"type":32},"2026-02-24",{"date":484,"type":21},"2030-02-24",{"name":38,"class":39},{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":492,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":18,"enrollmentInfo":494,"targetDuration":4,"studyType":22,"phases":496,"briefSummary":497,"conditions":498,"keywords":500,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":132},"100423590","exercise-and-patient-education-compared-with-usual-care-in-patients-with-hip-dysplasia-100423590","NCT04795843","Exercise and Patient Education Compared With Usual Care in Patients With Hip Dysplasia","MovetheHip-trial: The Effectiveness of Exercise and Patient Education Compared With Usual Care on Self-reported Pain in Patients With Hip Dysplasia","MovetheHip","Inclusion Criteria:\n\n* Radiographically verified hip dysplasia by a Wiberg's centre edge (CE) angle of 10-25 degrees and an acetabular Index (AI) angle \\>10 degrees\n* Hip and\u002For groin pain as primary pain for at least three months\n* Candidate for periacetabular osteotomy (PAO) but unwilling to undergo PAO, or on a waiting list for surgery (PAO) for 12 months or longer\n* Not candidate for PAO (negative impingement test, BMI \\>25, hip osteoarthritis, age \\>45 years or reduced hip range of motion)\n\nExclusion Criteria:\n\n* Self-reported pain score \\>80 points measured with Copenhagen Hip and Groin outcome score\n* Any major planned surgery (i.e. arthroplastic surgery or discectomy surgery)\n* BMI \\>35\n* Acetabular retroversion defined by crossover sign and posterior wall sign\n* Calvé Legg Perthes or epiphysiolysis\n* Previous pelvic\u002Fhip surgery in index limb\n* Previous pelvic\u002Fhip surgery within the last 2 years in contralateral limb\n* Previous surgery due to herniated disc or spondylodesis\n* Previous arthroplastic surgery in the hip, knee or ankle\n* Physical (pregnancy\u002Ftrauma), neurological, medical or rheumatic conditions severely affecting the hip function\n* Inadequacy in written and spoken Danish, mental illness or other conditions affecting the ability to follow mandatory procedures for participation",{"count":495,"type":21},200,[54],"This effectiveness trial will investigate if patients with hip dysplasia randomised to exercise and patient education have a different mean change in self-reported pain measured by the Copenhagen Hip and Groin Outcome Score (HAGOS) compared with those randomised to usual care over a six-month follow-up period.\n\nParticipating patients will be allocated to either exercise and patient education or usual care. Alongside this, a health-economic study and a process-evaluation study will be conducted.",[499],"Hip Dysplasia",[501,152,502,503,504,505,506,507],"Hip Dislocation, Congenital","Patient education","Usual care","Effectiveness","Cost-effectiveness","Process evaluation","Periacetabular osteotomy",{"date":509,"type":32},"2026-05-15",{"date":511,"type":32},"2021-04-16",{"date":513,"type":21},"2027-12",{"name":38,"class":39},{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":521,"targetDuration":523,"studyType":337,"phases":4,"briefSummary":524,"conditions":525,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":534,"locationsCount":40},"100469499","quality-of-life-and-surgery-in-diverticular-disease-100469499","NCT05393609","Quality of Life and Surgery in Diverticular Disease","Inclusion Criteria:\n\n* Referred to surgical clinic due to diverticular disease\n* Colonic diverticula verified by CT or endoscopy\n\nExclusion Criteria:\n\n* Previous colonic resection other than appendectomy\n* Previous or current colorectal cancer\n* Previous or current disseminated cancer\n* Inflammatory bowel disease\n* Psychiatric disorder influencing the ability to answer questionnaires\n* Inadequate Danish",{"count":522,"type":21},250,"1 Year","Diverticular disease is one of the most common diseases of the gastrointestinal tract in industrial countries. Prevalence and admission rate due to diverticular disease increases.\n\nSymptomatic patients usually present with acute uncomplicated or complicated diverticulitis. Recurrence rates of complicated diverticulitis are estimated to 10-30%. Recurrences, chronic complications or persisting pain, here collectively referred to as chronic diverticular disease, may be treated by elective sigmoidectomy. Currently, there is no specific criteria for elective surgery, but only a recommendation of a tailored approach depending on the patient's symptoms.\n\nIt is well established that diverticular disease has a negative impact on quality of life (QoL). Elective laparoscopic sigmoidectomy may increase QoL.\n\nIn this prospective study, we will prospectively examine QoL, patient-related outcomes and peri- and postoperative outcome of elective sigmoidectomy for chronic diverticular disease, and compare it to conservatively treated patients.",[526,527,528],"Diverticulitis Colon","Quality of Life","Diverticular Disease of Left Side of Colon","2026-05-11",{"date":159,"type":32},{"date":532,"type":32},"2022-04-22",{"date":513,"type":21},{"name":38,"class":39},{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":22,"phases":545,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":4},"100640947","phase-4-infusion-of-furosemide-to-improve-diuretic-efficiency-in-acute-heart-failure-100640947","NCT07577596","Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure","Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure (INFUSE-AHF)","INFUSE-AHF","Inclusion Criteria:\n\n* Clinical diagnosis of acute heart failure with volume overload\n* At least 1 sign of volume overload\n* Anticipated intravenous furosemide treatment for at least 3 days\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Shock\n* Patient requiring treatment with inotropes or vasopressors\n* Current or planned use of renal replacement therapy or ultrafiltration\n* Patient with a renal transplant\n* Patients who are pregnant or breastfeeding\n* Severe hypokalaemia, defined as potassium less than 2.5 mmol\u002FL, or severe hyponatremia, defined as sodium less than 125 mmol\u002FL\n* Allergy to furosemide and its components",{"count":544,"type":21},436,[24],"Acute heart failure is a condition where the heart suddenly cannot pump blood well enough for the body's needs. Many people admitted to the hospital with acute heart failure have too much fluid in the body. This can cause shortness of breath, swelling, and the need for treatment with water-removing medicine.\n\nFurosemide is a commonly used water-removing medicine that is given into a vein to treat fluid overload. It can be given in different ways. One way is as a continuous infusion, where the medicine is given slowly over time through a pump. Another way is as repeated injections given several times a day. It is not known whether one of these ways is better than the other for removing excess fluid in people with acute heart failure.\n\nThe purpose of this study is to compare two ways of giving furosemide into a vein: Continuous infusion started with an initial extra dose, and bolus injections given three times a day. About 436 adults admitted to hospitals in Denmark with acute heart failure and fluid overload will take part. Participants will be randomly assigned to one of the two treatment groups. This means that chance will decide which treatment method each participant receives.\n\nThe main thing the researchers will measure is how much body weight participants lose about 3 days after randomization. Weight loss is used as a measure of how much excess fluid has been removed.",[548,549],"Acute Heart Failure","Volume Overload","2026-05-05",{"date":529,"type":32},{"date":553,"type":21},"2026-05-01",{"date":555,"type":21},"2027-10-01",{"name":38,"class":39},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":22,"phases":565,"briefSummary":566,"conditions":567,"keywords":570,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":40},"100619192","focused-acceptance-and-commitment-therapy-fact-for-stress-anxiety-and-depression-100619192","NCT07341425","Focused Acceptance and Commitment Therapy (FACT) for Stress, Anxiety, and Depression","A Study Protocol for a Randomized Controlled Study of Focused Acceptance and Commitment Therapy (FACT)","Inclusion Criteria:\n\n(i) age ≥ 18 years, (ii) clinically relevant symptoms of distress ≥ 4 \\[53\\] and either symptoms of anxiety measured with the Generalized Anxiety Disorders (GAD ≥ 9 \\[54\\]) questionnaire and\u002For symptoms of depression with assessed with the Patient Health Questionnaire (PHQ-9 ≥ 10 \\[55\\]) and\u002For symptoms of stress measured with the Perceived Stress Scale (PSS ≥ 14), (iii) Danish language proficiency, (iv) ability and willingness to give informed consent, (v) no or stable antidepressant\u002Fantianxiety medication (i.e., same dosage for ≥ 6 weeks), (vi) access to either a smartphone, tablet, or computer with a video camera\n\nExclusion Criteria:\n\n(i) currently receiving other psychotherapy or counseling for the same problem, (iii) a history of bipolar disorder, (ii) current or past psychotic disorder, (iv) substance abuse or dependence judged to require treatment, (v) suicide risk requiring immediate hospitalization.",{"count":261,"type":21},[54],"This study is an interventional study examining the feasibility and acceptability of Focused Acceptance and Commitment Therapy (FACT) as a short-term intervention. Sixty participants will be randomized to either an intervention group (FACT; receiving a maximum of 250 min treatment) or a waitlist control group (receiving treatment after four months). Inclusion criteria are elevated symptoms of anxiety (GAD-7 ≥ 9), depression (PHQ-9 ≥ 10), and\u002For stress (PSS ≥ 14). Participants will complete self-report questionnaires at baseline, post-treatment, and at 1- and 3-month follow-ups. Additionally, brief session questionnaires will be completed before and after each session. Recruitment will take place through general practi-tioners in the Aarhus area.",[568,569],"Focused Acceptance and Commitment Therapy (FACT)","Wailist",[571,572,573],"FACT","Focused Acceptance and Commitment Therapy","Brief interventions","2026-04-28",{"date":576,"type":32},"2026-05-04",{"date":578,"type":32},"2026-01-06",{"date":580,"type":21},"2028-06-30",{"name":38,"class":39},{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":590,"targetDuration":4,"studyType":22,"phases":592,"briefSummary":593,"conditions":594,"keywords":597,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":620},"100570664","phase-4-treatment-with-aspirin-alone-versus-aspirin-in-combination-with-fondaparinux-before-early-coronary-assessment-in-patients-with-non-st-elevation-myocardial-infarction-100570664","NCT06710184","Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction","Aspirin Versus Aspirin and Fondaparinux Prior to Early Invasive Strategy in Patients With NSTEMI","FOXY","Inclusion Criteria:\n\n* Diagnosis of NSTEMI verified by:\n\n  * Rise or\u002Fand fall in cardiac troponin (cTN) and\n  * Symptoms of acute ischemia or ECG-changes compatible with acute ischemia.\n* Age above 18 years old\n* Expected remaining lifespan above 1 year\n* Informed consent\n\nExclusion Criteria:\n\n* Treatment with any anticoagulants before enrollment and randomization\n\n  * Including any direct anticoagulant (DOAC), LMWH, UFH or warfarin.\n* Not possible with CAG and PCI within 72 hours\n* Unsuitable for CAG and possible PCI due to poor condition\n* Estimated glomerular filtration rate (eGFR) \\\u003C 20 ml\u002Fmin\u002F1.73m2\n* Known liver disease\n* Active bleeding or high risk of bleeding where treatment with Fondaparinux is contraindicated.\n* Anemia (B-Hemoglobin \\\u003C 6.0 mmol\u002Fl)\n* Pregnancy or breastfeeding\n* Endocarditis\n* Indication for acute CAG before enrollment and randomization:\n\n  * ST-elevation Myocardial Infarction (STEMI)\n  * Patients classified as \"Very High Risk\" according to ESC guidelines, defined as(1):\n\n    * Hemodynamic instability (in need of inotropic support) or cardiogenic shock (DANGER-SHOCK criteria (20)) at time of admission.\n    * Acute heart failure because of presumed acute ischemia\n    * Life-threatening arrhythmias or cardiac arrest\n    * Mechanical complications (such as papillary muscle rupture with acute mitral regurgitation, free wall rupture and interventricular rupture)",{"count":591,"type":21},5076,[24],"The main goal of this study is to compare two treatments in patients with a specific type of heart attack called Non-ST-elevation Myocardial Infarction (NSTEMI). The investigators want to find out whether using aspirin alone is as effective and safer than using aspirin together with a second blood thinner called fondaparinux.\n\nBoth treatments will be given before a scheduled heart procedure called coronary angiography (CAG), which may include balloon dilation and stent placement (PCI) if needed.\n\nThe current guidelines recommend using aspirin in combination with a second blood thinner like fondaparinux before CAG and possible PCI. However, these recommendations are based on studies from the 1990s, a time when invasive procedures were not standard practice for these patients. In contrast, nearly all patients with NSTEMI in Denmark (96%) now undergo CAG within 72 hours. This change in practice raises questions about whether the older studies still provide a valid foundation for today's guidelines.\n\nThe study aims to answer two questions:\n\n1. Is aspirin alone as effective as aspirin combined with fondaparinux before early CAG and possible PCI?\n2. Is aspirin alone safer, with a lower risk of severe bleeding, compared to the combination treatment?\n\nTo answer these questions, the investigators will enroll about 5,000 patients with NSTEMI. Participants will be randomly assigned to receive either aspirin alone or aspirin with fondaparinux. The investigators will monitor them for 30 days to compare outcomes such as death, new heart attacks, the need for urgent CAG before the scheduled, and severe bleeding.",[595,596],"NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)","Acute Myocardial Infarction (AMI)",[598,599,600,601,602,603,604,605,606,607,608,609,95,610,611,612,613],"Acute Myocardial Infarction","Non-ST Segment Elevation Myocardial Infarction","Aspirin","Fondaparinux","Anticoagulation","Coronary Angiography","Percutaneus Coronary Intervention","Acute Coronay Syndrome","Early Invasive Treatment","Refractory ischemia","Bleeding risk","Mortality","New Myocardial Infarction","Non-inferiority Trial","Multicenter Study","Antithrombotic",{"date":576,"type":32},{"date":616,"type":32},"2025-05-01",{"date":618,"type":21},"2029-07-01",{"name":38,"class":39},10,{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":627,"eligibilityCriteria":628,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":629,"targetDuration":4,"studyType":22,"phases":631,"briefSummary":632,"conditions":633,"keywords":636,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":640,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":646},"100563321","response-colorectal-cancer-survivors-follow-up-care---now-digital-and-need-based-100563321","NCT06614647","RESPONSE: Colorectal Cancer Survivors' Follow-up Care - Now Digital and Need-based","RESPONSE: Colorectal Cancer Survivors' Follow-up Care - Now Digital and Need-based: A National Interventional Effectiveness Trial for Stage I and II Patients","RESPONSE","Inclusion Criteria:\n\n1. Patients treated for stage I and low risk stage II colorectal cancer with curative intend.\n2. Age 18 years or older.\n3. Understands spoken and written Danish language.\n4. Able to use digital care-guide as smartphone application.\n5. The patient is also included in DANISH.MRD part 1.\n\nExclusion Criteria:\n\n1. Patients who are unlikely to comply with the protocol, unable to return for subsequent visits and\u002For otherwise considered by the PIs to be unlikely to complete the study.\n2. Patients who are not able or willing to adhere to the digital platform.\n3. Patients treated only with local endoscopic resection, e.g.,Transanal Endoscopic microsurgery (TEM).",{"count":630,"type":21},400,[54],"Over the last decades, the 3-year recurrence rates for patients with stage I and II colorectal cancer have decreased to just 5% and 12%. The follow-up program offered to stage I and low-risk stage II patients has not changed accordingly and is still focused solely on recurrence detection. Moreover, it is a one-size-fits-all program, i.e. most of the follow-up resources are spent on non-recurrence patients who do not benefit.\n\nUp to 50% of cancer survivors suffer from reduced quality of life related to fear of cancer recurrence, treatment-related psychological distress, and\u002For severe late adverse effects of a biopsychosocial and\u002For organ-specific origin. Today many of these symptoms can be treated effectively. However, no systematic program aimed at monitoring and addressing the symptoms has been implemented yet.\n\nThe current project is testing a newly developed, digitally managed, patient-centered follow-up program that focuses on individual patient needs, including fear of cancer recurrence, psychological well-being, management of late adverse effects, and recurrence surveillance. This new program will be compared to the current standard of care in a national network of 11 colorectal cancer surgical centers in four of five Danish regions.\n\nPatients in the intervention group will receive the following:\n\n1. Risk-stratified circulating tumor DNA (ctDNA) guided recurrence surveillance.\n2. Late adverse effects monitoring with electronic patient-reported outcome measures, which are validated questionnaires that can identify and qualify late adverse effects.\n3. Systematic treatment for organ-specific and\u002For biopsychosocial late adverse effects.\n4. A digital care guide, to support the patient trajectory through the follow-up program, as a smartphone app.\n\nPatients in the standard group will receive standard-of-care follow-up.\n\nThe primary study endpoint will be the difference in health-related quality of life between the intervention and standard group. Secondary outcomes include e.g., comparison of health-related costs, differences in fear of cancer recurrence, recurrence-free survival, and patient satisfaction.\n\nThe investigators expect the new follow-up program to be better than the standard-of-care program in terms of the primary endpoint - quality of life - without compromising recurrence detection, and without increasing costs.",[634,527,635],"Colorectal Cancer","Survivorship",[637,638,639],"Circulating Tumor DNA","Organ-specific late effects","Biopsychosocial Late effects",{"date":576,"type":32},{"date":642,"type":32},"2024-09-15",{"date":644,"type":21},"2030-02-01",{"name":38,"class":39},9,{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":653,"eligibilityCriteria":654,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":655,"targetDuration":4,"studyType":22,"phases":657,"briefSummary":658,"conditions":659,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":667,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":673,"locationsCount":132},"100554166","danish-vulva-cancer-recurrence-study-100554166","NCT06495554","Danish Vulva Cancer Recurrence Study","The Value of Patient-reported Outcome Measure Assessment and Circulating Tumor-DNA to Detect Early Relapse During Surveillance in Women With Vulva Cancer","DaVulvaRec","Inclusion Criteria:\n\n* Primary or recurrent biopsy-verified squamous cell carcinoma of the vulva\n* ≥ 18 years of age\n* Able to understand oral and written information in Danish\n\nExclusion Criteria:\n\n* Active treatment for concurrent cancer and\u002For dissemination of concurrent cancer",{"count":656,"type":21},1295,[54],"The overall aim is to investigate different aspects of recurrence detection in women with vulva cancer (VC) to identify optimal treatment- and surveillance programs.\n\nDaVulvaRec is a Danish nationwide multicenter study with patient inclusion from Aarhus University Hospital and Rigshospitalet, Denmark. Applying a mixed method research design, the investigators will collect and analyze patient-reported outcome measures in combination with procedural data to evaluate symptomatology and map actions taken during the patient's pathway from primary disease to recurrence. Furthermore, the investigators aim to examine if circulating tumor-DNA (ctDNA) can be detected in liquid biopsies from VC patients. All patients will be followed for two years or until recurrence. Patient-reported outcome measures will be completed every four months during surveillance, and liquid biopsies will be collected prospectively for later analyses.\n\nTotal number of patients to be included is 295 according to a power calculation. All patients in the clinical study will be included in the intervention group, while data on a historical control group will be obtained from The Danish Gynecological Cancer Database. Hence, the control group will consist of 1000 VC patients diagnosed between 2011-2022.\n\nHypotheses:\n\n* All patients with VC will have specific tumor markers in the primary tumor that will be detectable in liquid biopsies as ctDNA at the time of diagnosis.\n* Measurement of ctDNA after primary treatment and during surveillance will allow detection of residual disease, improve allocation for adjuvant treatment, and will allow early detection of recurrent VC.\n* Proactive use of repeated PROM assessments in combination with procedural actions during surveillance will allow early detection of recurrent VC and early identification of late effects after treatment.",[660,661,662,663,664,665,666,637,635],"Vulva Cancer","Vulva Neoplasm","Vulvar Cancer","Vulva Disease","Vulvar Neoplasms","Vulvar Diseases","PROM",{"date":668,"type":32},"2026-04-29",{"date":670,"type":32},"2024-08-15",{"date":672,"type":21},"2030-12-31",{"name":38,"class":39},{"id":675,"slug":676,"hasResults":12,"nctId":677,"briefTitle":678,"officialTitle":679,"acronym":680,"eligibilityCriteria":681,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":682,"enrollmentInfo":683,"targetDuration":4,"studyType":22,"phases":684,"briefSummary":685,"conditions":686,"keywords":690,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":692,"startDateStruct":693,"completionDateStruct":695,"leadSponsor":697,"locationsCount":384},"100472167","incremental-value-of-magnetic-resonance-imaging-in-selection-of-pancreatic-cancer-patients-for-surgery-100472167","NCT05428358","Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery","Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery (MAGIPAC): A Randomized Clinical Trial.","MAGIPAC","Inclusion criteria:\n\n* Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board\n* No liver metastases on CT\n* At least 18 years old and able to provide informed consent\n* Expected pancreatic ductal adenocarcinoma based on CT scan\n\nExclusion criteria:\n\n* Metastatic disease\n* Prior receipt of neoadjuvant chemotherapy or downstaging\u002F-sizing treatment\n* Comorbidity rendering major surgery unfeasible (inoperable)\n* No informed consent\n* Unable to undergo MRI (Kidney insufficiency (eGFR \\\u003C 60 ml\u002Fmin\u002F1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker)\n* Postoperative histology other than adenocarcinoma of pancreato-biliary origin.\n* MRI with liver-specific contrast performed during standard workup.","99 Years",{"count":495,"type":21},[54],"The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.",[687,688,689],"Pancreatic Cancer","Pancreatic Neoplasm","Liver Metastases",[691],"magnetic resonance imaging",{"date":668,"type":32},{"date":694,"type":32},"2022-08-30",{"date":696,"type":21},"2028-12-01",{"name":38,"class":39},""]